Test Predicts Patient Benefit From Breast Cancer Drug

It spots those with resistance to Herceptin

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

En Español

MONDAY, Aug. 23, 2004 (HealthDayNews) -- A new way to accurately predict how individual breast cancer patients will react to the anticancer drug trastuzumab (Herceptin) has been identified by researchers at the Texas M.D. Anderson Cancer Center, in Houston.

This finding could help breast cancer patients who aren't likely to respond to the drug to avoid unnecessary side effects and costs associated with the treatment. The study results also offer scientists new information that may help them find ways to overcome resistance to cancer treatments.

This study found that a deficiency of PTEN, an important tumor suppressor, is an indicator for trastuzumab resistance.

The study appears in the August issue of Cancer Cell.

More information

The American Cancer Society has more about breast cancer.

SOURCE: Cell Press, news release, Aug. 23, 2004

--

Last Updated:

Related Articles